Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22654312 | 1.00 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL31584148 | 1.00 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL31259011 | 1.00 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL22408648 | 1.00 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL21222814 | 1.00 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL21223782 | 1.00 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL22408647 | 1.00 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL21222782 | 1.00 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL27190437 | 0.94 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL27190438 | 0.94 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325561-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEAGEN INC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20220072146-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEAGEN INC (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3756663-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | Seagen Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3057585-B1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEATTLE GENETICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20160310612-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEATTLE GENETICS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072146-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | EGFR, HDGF, CD47 | TLR2 402/4885KMT2A 3859/4885MDM2 652/4885 |
| US-20240325561-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | EGFR, HDGF, CD47 | TLR2 406/4885KMT2A 3862/4885MDM2 629/4885 |
| US-20160310612-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | EGFR, HDGF, CD47 | TLR2 406/4885KMT2A 3862/4885MDM2 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.